Perospirone (SM-9018 Free Base): Atypical Antipsychotic & Kv1.5 Modulator for Schizophrenia Research

Executive Summary: Perospirone (SM-9018 free base) is an orally active, second-generation antipsychotic classified as a serotonin–dopamine antagonist (SDA) with high affinity for 5-HT2A (0.6 nM) and D2 (1.4 nM) receptors, and partial agonism at 5-HT1A (2.9 nM) [APExBIO]. Its mechanism addresses both positive and negative symptoms of schizophrenia by modulating serotonergic and dopaminergic pathways [Mun et al., 2025]. Unique to Perospirone among SDAs, it inhibits vascular Kv1.5 channels in a concentration-dependent, use-independent manner [Mun et al., 2025]. This off-target profile has implications for cardiovascular research. Perospirone is supplied by APExBIO (SKU BA5009) and is intended strictly for research use.

Biological Rationale

Schizophrenia is a complex neuropsychiatric disorder characterized by dysregulation of serotonergic and dopaminergic signaling pathways. Positive symptoms (e.g., hallucinations) are linked to hyperdopaminergic activity, while negative symptoms (e.g., social withdrawal) often reflect serotonergic dysfunction (Mun et al., 2025). Effective antipsychotic agents must address both neurotransmitter systems. Perospirone (SM-9018 free base) was developed as a dual-action agent targeting 5-HT2A (serotonin) and D2 (dopamine) receptors, with added partial agonism for 5-HT1A, which may reduce extrapyramidal side effects compared to typical antipsychotics (Mun et al., 2025). Recent findings show that Perospirone also modulates Kv1.5 potassium channels, which are critical in vascular smooth muscle cell function and cardiovascular homeostasis (Mun et al., 2025). This dual activity expands its application to modeling both neuropsychiatric and vascular phenomena.

Mechanism of Action of Perospirone (SM-9018 free base)

Perospirone acts as a potent antagonist at the 5-HT2A receptor (Ki = 0.6 nM) and the dopamine D2 receptor (Ki = 1.4 nM), and as a partial agonist at the 5-HT1A receptor (Ki = 2.9 nM) [product source]. This receptor-binding profile is central to its antipsychotic efficacy. 5-HT2A antagonism modulates dopamine release in the mesocortical pathway, improving negative and cognitive symptoms. D2 antagonism alleviates positive symptoms by reducing dopaminergic hyperactivity in the mesolimbic pathway. Partial agonism at 5-HT1A receptors further attenuates extrapyramidal symptoms and may enhance cognitive outcomes [Mun et al., 2025].

In addition, Perospirone inhibits voltage-gated Kv1.5 potassium channels in vascular smooth muscle cells. This effect is concentration-dependent, with an IC50 of 20.54 ± 2.89 μM, and is not use-dependent, indicating a direct but non-state-specific interaction with the channel [Mun et al., 2025]. Kv1.5 modulation may influence vascular tone and cardiovascular risk profiles.

Evidence & Benchmarks

• Perospirone exhibits high affinity for human 5-HT2A (Ki = 0.6 nM), D2 (Ki = 1.4 nM), and 5-HT1A (Ki = 2.9 nM) receptors at physiological pH (7.4) and 25°C (APExBIO).
• In rabbit coronary arterial smooth muscle cells, Perospirone inhibits Kv1.5 channels with IC50 = 20.54 ± 2.89 μM; inhibition is concentration-dependent and use-independent (Mun et al., 2025).
• Blockade of Kv1.5 was partially attenuated by the selective Kv1.5 inhibitor DPO-1, confirming the subtype-specific effect (Mun et al., 2025).
• Perospirone did not alter Kv activation/inactivation kinetics, suggesting non-state-dependent binding (Mun et al., 2025).
• Compared to other SDAs, Perospirone is used mainly in Japan, reflecting regional differences in approval and pharmacovigilance (Mun et al., 2025).

Contrast: For further discussion of Perospirone's unique Kv1.5 activity, see this article; the current piece extends prior analyses by integrating recent peer-reviewed evidence on concentration-dependent channel modulation. For scenario-driven guidance on in vitro protocol optimization, refer to this resource, whereas this dossier focuses on mechanistic and benchmarking data. To understand Perospirone's translational potential for neuropsychiatric and vascular modeling, our article provides an updated synthesis versus prior reviews.

Applications, Limits & Misconceptions

Perospirone (SM-9018 free base) is validated for preclinical schizophrenia models, especially when both serotonergic and dopaminergic signaling must be interrogated. Its Kv1.5 inhibition profile makes it a candidate for vascular research, particularly in the context of antipsychotic-induced cardiovascular effects. The compound is not approved for clinical or diagnostic use outside research settings [APExBIO].

Common Pitfalls or Misconceptions

• Not for human or veterinary use: Perospirone (BA5009) is strictly for in vitro and preclinical research; it is not a therapeutic product.
• Not a broad-spectrum ion channel blocker: Perospirone selectively inhibits Kv1.5 channels and does not broadly block all K+ channel subtypes (Mun et al., 2025).
• Limited geographical clinical approval: Its clinical use is largely restricted to Japan due to region-specific regulatory and safety data (Mun et al., 2025).
• Stability concerns in solution: Long-term storage of Perospirone in DMSO solution is not recommended; solid form at -20°C is optimal (APExBIO).
• No effect on Kv channel activation/inactivation kinetics: Perospirone does not alter gating properties, only channel availability (Mun et al., 2025).

Workflow Integration & Parameters

Perospirone (SM-9018 free base, SKU BA5009) is supplied as a solid (molecular weight 426.57, C23H30N4O2S). For optimal stability, store at -20°C in a desiccated environment; avoid repeated freeze-thaw cycles. For cell-based assays, prepare a 10 mM stock in DMSO immediately prior to use; avoid long-term solution storage. Shipping is under blue ice for small molecules. APExBIO provides detailed protocols for receptor binding and Kv channel assays. Researchers should titrate compound concentrations based on the target pathway: 1–100 nM for receptor assays, and up to 100 μM for ion channel studies, as Kv1.5 inhibition occurs at higher concentrations (Mun et al., 2025). For lot-specific data sheets, see the BA5009 product page.

Conclusion & Outlook

Perospirone (SM-9018 free base) stands out as a research-grade atypical antipsychotic, uniquely combining potent serotonin–dopamine receptor antagonism with Kv1.5 channel inhibition. This dual action enables sophisticated modeling of both schizophrenia and vascular side-effects in preclinical systems. As emerging findings clarify its off-target effects, Perospirone offers a powerful tool for both neuroscience and cardiovascular disorder modeling. APExBIO supports reproducible research with validated supply and technical documentation. For the latest protocol updates and safety data, consult the official BA5009 listing.